ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1671
0,44%
Bitcoin
68.844,68
1,35%
Brent Oil
81,965
0,81%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Y mAbs Therapeutics Inc (YMAB)

  7. Y mAbs Therapeutics Inc (YMAB) Notícias

YMAB

Y mAbs Therapeutics (YMAB)

Y mAbs Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:YMAB
DataHoraFonteTítuloCódigoCompanhia
23/05/202419:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
21/05/202417:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202417:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:YMABY mAbs Therapeutics Inc
07/05/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202417:05GlobeNewswire Inc.Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
26/04/202408:05GlobeNewswire Inc.Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NASDAQ:YMABY mAbs Therapeutics Inc
25/04/202417:05GlobeNewswire Inc.Y-mAbs to Present at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
14/03/202410:05GlobeNewswire Inc.Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202409:30GlobeNewswire Inc.Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsNASDAQ:YMABY mAbs Therapeutics Inc
29/02/202419:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:YMABY mAbs Therapeutics Inc
29/02/202418:05GlobeNewswire Inc.Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
16/02/202409:30GlobeNewswire Inc.Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024NASDAQ:YMABY mAbs Therapeutics Inc
06/02/202417:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:YMABY mAbs Therapeutics Inc
02/01/202418:05GlobeNewswire Inc.Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
13/12/202318:05GlobeNewswire Inc.Y-mAbs Therapeutics Added to the NASDAQ Biotechnology IndexNASDAQ:YMABY mAbs Therapeutics Inc
13/11/202318:05GlobeNewswire Inc.Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
08/11/202319:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
31/10/202308:05GlobeNewswire Inc.Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023NASDAQ:YMABY mAbs Therapeutics Inc
18/10/202317:05GlobeNewswire Inc.Y-mAbs Names Michael Rossi as President and Chief Executive Officer and DirectorNASDAQ:YMABY mAbs Therapeutics Inc
17/10/202319:01Dow Jones NewsY-mAbs Therapeutics New Drug Application Gets FDA ClearanceNASDAQ:YMABY mAbs Therapeutics Inc
17/10/202317:05GlobeNewswire Inc.Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADANASDAQ:YMABY mAbs Therapeutics Inc
16/10/202317:05GlobeNewswire Inc.Y-mAbs Announces Publication in CancersNASDAQ:YMABY mAbs Therapeutics Inc
21/09/202317:05GlobeNewswire Inc.Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric OncologyNASDAQ:YMABY mAbs Therapeutics Inc
06/09/202317:05GlobeNewswire Inc.Y-mAbs to Participate at Upcoming Investor Conferences in SeptemberNASDAQ:YMABY mAbs Therapeutics Inc
10/08/202317:05GlobeNewswire Inc.Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
02/08/202317:05GlobeNewswire Inc.Y-mAbs to Participate at Upcoming Investor ConferencesNASDAQ:YMABY mAbs Therapeutics Inc
01/08/202317:05GlobeNewswire Inc.Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023NASDAQ:YMABY mAbs Therapeutics Inc
09/06/202319:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:YMABY mAbs Therapeutics Inc
09/06/202318:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:YMABY mAbs Therapeutics Inc
26/05/202310:00GlobeNewswire Inc.Y-mAbs Announces Presentation of Naxitamab Data at ASCONASDAQ:YMABY mAbs Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:YMAB

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RNEW4
RENOVA PN
BOV
PRIO3
PETRORIO ON
BOV
AMER3
Americanas ON
BOV
AZEV4
AZEVEDO PN
BOV
GOLL4
GOL PN
BOV
HOOT4
HOTEIS OTHON PN
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
SGPS3
SPRINGS ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
COGN3
COGNA ON
BOV
RPMG3
PET MANGUINH ON
BOV
TELB4
TELEBRAS PN
BOV
HAGA3
HAGA ON
BOV
CLSA3
Clear Sale ON
BOV
CEAB3
C&A ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados